For people whose Graves' disease returns after initial treatment, taking a low daily dose of methimazole long-term keeps thyroid hormone levels stable more often than using radioactive iodine or taking methimazole again for a limited time.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of randomized trials would determine whether continuous low-dose MMI consistently leads to better euthyroidism rates than RAI or second-course MMI across diverse populations, accounting for heterogeneity in dosing, duration, and patient characteristics.
A systematic review and meta-analysis of all published randomized controlled trials comparing continuous low-dose MMI (≤5 mg/day) versus RAI or second-course MMI in adults with relapsed Graves' disease, including only studies with ≥2 years of follow-up, standardized thyroid function monitoring, and blinded outcome assessment. Primary outcome: proportion of time in euthyroidism over 5+ years. Secondary outcomes: relapse rates, hypothyroidism incidence, quality of life, and adverse events.
A randomized trial would determine whether assigning patients to continuous low-dose MMI versus RAI directly causes improved euthyroidism rates, independent of patient preference or selection bias.
A multicenter, double-blind, placebo-controlled RCT enrolling 300 adults aged 18–65 with confirmed relapsed Graves' disease after initial MMI therapy, randomized 1:1:1 to continuous low-dose MMI (5 mg/day), RAI (15 mCi), or second-course MMI (24+ months). Primary outcome: proportion of euthyroid visits over 5 years, measured by quarterly TSH/free T4. Secondary outcomes: TRAb clearance, TED progression, weight change, and quality of life (ThyPRO-39). All patients receive standardized follow-up and adherence monitoring.
A prospective cohort with standardized treatment assignment and adjustment for confounders (e.g., TRAb levels, smoking, compliance) could strengthen the association between continuous MMI and euthyroidism by reducing selection bias.
A prospective cohort study following 500 adults with relapsed Graves' disease, prospectively assigning treatment based on predefined clinical criteria (not patient choice), with blinded thyroid function assessments every 3 months for 7 years. Covariates including TRAb titers, adherence (pill counts), smoking, and baseline TED status are collected at baseline and adjusted in multivariate analysis.
A case-control study could identify whether patients achieving sustained euthyroidism on continuous MMI differ in baseline characteristics (e.g., TRAb levels, age, weight) from those who develop hypothyroidism after RAI or relapse after second-course MMI.
A case-control study comparing 100 patients with sustained euthyroidism (>80% of visits) on continuous MMI to 100 patients with persistent hypothyroidism after RAI or relapse after second-course MMI, matched for age, sex, TRAb levels at relapse, and baseline TED. Exposure history (dose, duration, adherence) and comorbidities are retrospectively assessed.
A cross-sectional survey could estimate the prevalence of euthyroidism in patients currently on continuous MMI versus RAI, but cannot determine whether one treatment leads to better outcomes over time.
A cross-sectional survey of 1000 adults with relapsed Graves' disease currently on continuous MMI, RAI, or second-course MMI, measuring current thyroid function status, quality of life, and adherence at a single time point.